Fasnall( —— )

Catalog No. M27877 CAS No. 929978-58-5

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Fasnall
Note

Research use only, not for human use.
Brief Description

Fasnall is a selective FASN inhibitor that acts through its co-factor binding sites. Fasnall shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly in combination with carboplatin.
Description

Fasnall is a selective FASN inhibitor that acts through its co-factor binding sites. Fasnall shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly in combination with carboplatin.
In Vitro

Cell Proliferation Assay Cell Line:MCF7, MDA-MB-468, BT474 and SKBR3 cells Concentration:50 μM Incubation Time:24 h, 48 h, 72 h, 96 h, 120 h Result:Inhibited the proliferation of aggressive cell lines, but showed lower activity in the non-tumorigenic cell line MCF10A.Apoptosis Analysis Cell Line:MCF7, MDA-MB-468, BT474 and SKBR3 cells Concentration:25 μM, 50 μM , 75 μM, 100 μM Incubation Time:24 h Result:Induced caspase-3 and caspase-7 activation.
In Vivo

Animal Model:Female MMTV-NEU mice bearing HER2+ breast cancer cellsDosage:15 mg/kg Administration:i.p.; twice weekly; 3 weeks Result:Reduced tumor volume, and increased the median survival of the MMTV-Neu mice to 63 days.
Synonyms

——
Pathway

Metabolic Enzyme/Protease
Target

Fatty Acid Synthase
Recptor

PFKFB3|PFKFB1|PFKFB2
Research Area

——
Indication

——

1.Boyd S, et al. Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3. J Med Chem. 2015 Apr 23;58(8):3611-25.

Calculator

molnova catalog